Research ExplorerPublications[PSA--Quo vadis?]

[PSA--Quo vadis?]

Standard

[PSA--Quo vadis?]. / Börgermann, C; Loertzer, H; Luboldt, H-J; Hammerer, P; Fornara, P; Graefen, Markus; Rübben, H.

In: UROLOGE, Vol. 48, No. 9, 9, 2009, p. 1008, 1010, 1012-1014.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Börgermann, C, Loertzer, H, Luboldt, H-J, Hammerer, P, Fornara, P, Graefen, M & Rübben, H 2009, '[PSA--Quo vadis?]', UROLOGE, vol. 48, no. 9, 9, pp. 1008, 1010, 1012-1014. <http://www.ncbi.nlm.nih.gov/pubmed/19680620?dopt=Citation>

APA

Börgermann, C., Loertzer, H., Luboldt, H-J., Hammerer, P., Fornara, P., Graefen, M., & Rübben, H. (2009). [PSA--Quo vadis?]. UROLOGE, 48(9), 1008, 1010, 1012-1014. [9]. http://www.ncbi.nlm.nih.gov/pubmed/19680620?dopt=Citation

Vancouver

Börgermann C, Loertzer H, Luboldt H-J, Hammerer P, Fornara P, Graefen M et al. [PSA--Quo vadis?]. UROLOGE. 2009;48(9):1008, 1010, 1012-1014. 9.

Bibtex

@article{0ad1c9101c4c4ef19762ff17bbf53cbd,
title = "[PSA--Quo vadis?]",
abstract = "Prostate cancer is the most frequent cancer in males. Because of the high cure rates, early detection of prostate cancer should identify organ-confined prostate cancers. An early detection examination should be performed annually starting at the age of 50 years and ending when life expectancy is less than 10 years. Digital rectal examination is supplemented by determination of prostate-specific antigen (PSA). Before the first PSA test, the patient must be informed of possible consequences such as biopsy recommendation and treatment options. A threshold of 4 ng/ml is defined as the indication for prostate biopsy. Imaging methods do not play a major role in early detection of prostate cancer today. Early detection identifies many latent prostate cancers, and patients may receive overtreatment. A possible solution is to change the early detection paradigm from detection of all prostate cancers to identification of aggressive ones. In this article, early detection is discussed based on the recent literature.",
keywords = "Humans, Male, Ambulatory Care methods, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Reproducibility of Results, Sensitivity and Specificity, Tumor Markers, Biological blood, Humans, Male, Ambulatory Care methods, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Reproducibility of Results, Sensitivity and Specificity, Tumor Markers, Biological blood",
author = "C B{\"o}rgermann and H Loertzer and H-J Luboldt and P Hammerer and P Fornara and Markus Graefen and H R{\"u}bben",
year = "2009",
language = "Deutsch",
volume = "48",
pages = "1008, 1010, 1012--1014",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - [PSA--Quo vadis?]

AU - Börgermann, C

AU - Loertzer, H

AU - Luboldt, H-J

AU - Hammerer, P

AU - Fornara, P

AU - Graefen, Markus

AU - Rübben, H

PY - 2009

Y1 - 2009

N2 - Prostate cancer is the most frequent cancer in males. Because of the high cure rates, early detection of prostate cancer should identify organ-confined prostate cancers. An early detection examination should be performed annually starting at the age of 50 years and ending when life expectancy is less than 10 years. Digital rectal examination is supplemented by determination of prostate-specific antigen (PSA). Before the first PSA test, the patient must be informed of possible consequences such as biopsy recommendation and treatment options. A threshold of 4 ng/ml is defined as the indication for prostate biopsy. Imaging methods do not play a major role in early detection of prostate cancer today. Early detection identifies many latent prostate cancers, and patients may receive overtreatment. A possible solution is to change the early detection paradigm from detection of all prostate cancers to identification of aggressive ones. In this article, early detection is discussed based on the recent literature.

AB - Prostate cancer is the most frequent cancer in males. Because of the high cure rates, early detection of prostate cancer should identify organ-confined prostate cancers. An early detection examination should be performed annually starting at the age of 50 years and ending when life expectancy is less than 10 years. Digital rectal examination is supplemented by determination of prostate-specific antigen (PSA). Before the first PSA test, the patient must be informed of possible consequences such as biopsy recommendation and treatment options. A threshold of 4 ng/ml is defined as the indication for prostate biopsy. Imaging methods do not play a major role in early detection of prostate cancer today. Early detection identifies many latent prostate cancers, and patients may receive overtreatment. A possible solution is to change the early detection paradigm from detection of all prostate cancers to identification of aggressive ones. In this article, early detection is discussed based on the recent literature.

KW - Humans

KW - Male

KW - Ambulatory Care methods

KW - Prostate-Specific Antigen blood

KW - Prostatic Neoplasms blood

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Tumor Markers, Biological blood

KW - Humans

KW - Male

KW - Ambulatory Care methods

KW - Prostate-Specific Antigen blood

KW - Prostatic Neoplasms blood

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Tumor Markers, Biological blood

M3 - SCORING: Zeitschriftenaufsatz

VL - 48

SP - 1008, 1010, 1012-1014

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 9

M1 - 9

ER -